Baclofen patients sue to remove dose limitWednesday’s Le Parisien (p11) announced that the top administrative court in France will decide on February 16 whether the dosage limit recently imposed by French authorities for alcohol addiction treatment baclofen should be removed or not.
Sanofi rejects Philippines’ demand for Dengue vaccine refundOn Tuesday, Les Echos (brief p15), and Le Figaro (brief p9) reported that Sanofi had rejected the Philippines’ demand for a refund for supplies of its dengue vaccine Dengvaxia bought before the suspension of the vaccination campaign.
Edmond de Rothschild raises 345 million euros for biotech fundThursday’s Les Echos (p22) reported on the 345 million euros of raised by Edmond de Rothschild Investment Partners (Edrip) for its Biotech and Medical Technologies fund, “the largest in the sector in Europe”.
Sanofi ready to grow in 2018Thursday’s Les Echos (p22) reported that Sanofi was ready to grow again in 2018, counting on both its specialty medicines and on acquisitions. (APMHE 56793, APMHE 56773).
New study to investigate how to increase immunotherapy efficacyMonday’s Les Echos (website) announced that two French cancer research institutions, Unicancer and Fondation ARC, have launched a new study that aims to understand the response factors to immunotherapies.
Simple blood test could avoid cancer drug toxicityFriday’s Le Figaro (p13) reports that a French study has established that 133 cancer patients died because of the toxicity of 5FU chemotherapy between 2005 and 2015, and 155 required critical care, noting that a simple blood analysis could prevent such events.
Stergiopoulos appointed CMO at IpsenThursday’s Les Echos (p35) said that Sortirions Stergiopoulos has been promoted to chief medical officer at Ipsen.
GSK expects stable results in 2018Thursday’s Les Echos (brief p22) briefly reported that GlaxoSmithKline expects stable results this year, also noting that the markets have not reacted favourably to the “blurring” around its results prospects.
16.4 billion-dollar loss for Teva in 2017Friday’s Les Echos (p18) reports on the 16.4 billion dollars loss recorded by Teva in 2017 (APMHE 56811).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.